Get the Stockscreener App
9.03
1.85%
-0.17
After Hours:
9.00
-0.03
-0.33%
Biocryst Pharmaceuticals Inc stock is traded at $9.03, with a volume of 3.71M.
It is down -1.85% in the last 24 hours and up +0.11% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$9.20
Open:
$9.22
24h Volume:
3.71M
Relative Volume:
0.74
Market Cap:
$2.29B
Revenue:
$874.84M
Net Income/Loss:
$263.86M
P/E Ratio:
7.5056
EPS:
1.2031
Net Cash Flow:
$327.41M
1W Performance:
+1.92%
1M Performance:
+0.11%
6M Performance:
+25.94%
1Y Performance:
-18.13%
1-Day Range:
$8.935
$9.305
1-Week Range:
$8.81
$9.395
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.03 | 2.34B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Resumed | Evercore ISI | Outperform |
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals earnings loom amid HAE market battle By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals earnings loom amid HAE market battle - Investing.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Secures Licensing Deal for Navenibart in Europe - GuruFocus
BioCryst Pharmaceuticals, Inc. Files Form 8-K with SEC – Company Details, Stock, and Contact Information (May 2026) - Minichart
BioCryst Licenses European Rights to HAE Drug Navenibart - TipRanks
BioCryst licenses navenibart rights in Europe for $70M upfront By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe. - Bitget
BioCryst (NASDAQ: BCRX) licenses navenibart in Europe for $70M upfront - Stock Titan
BioCryst lands $70M now, up to $275M more in Europe HAE deal - Stock Titan
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema - Yahoo Finance UK
Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains - Yahoo Finance
RBC Capital Raises BioCryst Pharmaceuticals Price Target to 14 Dollars - HarianBasis.co
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech - Insider Monkey
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
Vanguard Capital Management (NASDAQ: BCRX) discloses 12.96M-share stake, 5.16% - Stock Titan
5 Best Drug Stocks to Buy According to Analysts - Insider Monkey
BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday - MarketBeat
BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN
BioCryst to Present at Upcoming Investor Conferences - The Manila Times
BioCryst lines up two investor conference presentations in May and June - Stock Titan
Intellia Heads To FDA With Positive Phase III Results For Lonvo-Z - Citeline News & Insights
BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN
MSN Money - MSN
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
BioCryst gains amid takeover speculation - MSN
The Technical Signals Behind (BCRX) That Institutions Follow - Stock Traders Daily
BCRX Should I Buy - Intellectia AI
BCRX Price Today: BioCryst Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
[ARS] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) puts 7M-share incentive plan increase to stockholder vote - Stock Titan
BCRX (BioCryst Pharmaceuticals Inc.) drops 2.38 percent post Q4 2025 EPS miss despite 94 percent year over year revenue growth.Social Flow Trades - Cổng thông tin điện tử tỉnh Tây Ninh
BCRX (BioCryst Pharmaceuticals Inc.) reports steep Q4 2025 EPS miss, stock edges 0.21 percent lower in daily trading.Analyst Ratings - Cổng thông tin điện tử tỉnh Tây Ninh
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
There's No Escaping BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Muted Revenues - 富途牛牛
BCRX Stock Price, Quote & Chart | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and BioCryst (BCRX) - The Globe and Mail
Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is Hiring AI-Focused Rare Disease R&D Leader Sandeep Menon Altering The Investment Case For BioCryst (BCRX)? - Sahm
BioCryst to Report First Quarter 2026 Financial Results on May 6 - Sahm
BioCryst to File Peramivir NDA Supported by BARDA/HHS Funding - AOL.com
Lilly to acquire CrossBridge Bio for up to $300m - Pharmaceutical Technology
BioCryst to Report First Quarter 2026 Financial Results on May 6 | Nation/World | bdtonline.com - Bluefield Daily Telegraph
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):